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Introduction
The increased risk of breast cancer among women with a
family history of the disease is one of the oldest established
facts about the disease. This familial aggregation has been
the inspiration for studies to identify breast cancer suscep-
tibility genes that have borne fruit over the past decade,
and has been the basis for defining high-risk groups for
intervention studies (e.g. with tamoxifen). Yet despite the
fact that questions about family history are asked in almost
every epidemiological study of breast cancer, some impor-
tant questions about the quantitative relationship between
family history relationship have not been answered with
precision. Among these questions are the magnitude of the
risk according to the age of the women and the age of their
affected relative(s), the precise effect of numbers and
types of affected relatives, and the joint effects of family
history and other known risk factors.
Since only ~10–15% of women with breast cancer typi-
cally report a family history of breast cancer, individual epi-
demiological studies have not had the power to answer
these questions precisely. The recent analysis by the Col-
laborative Group on Hormonal Factors in Breast Cancer
[1] goes a long way toward resolving some of these
uncertainties. This group has brought together data from
52 studies, originally to evaluate the effects of oral contra-
ceptives and hormone replacement therapy. In the current
overview, the group examine risks according to family
history of breast cancer in a first-degree relative in over
58,000 cases and in nearly 102,000 controls.
Summary of main findings
The main results from the overview [1] are straightforward
to summarise. The results of the study are mainly
expressed in terms of the risk ratio (or relative risk) of
breast cancer associated with a family history; that is, the
ratio of the incidence rate of breast cancer in relatives of
breast cancer cases to the incidence in the relatives of
controls. These risk ratios were estimated from the
case–control studies in the usual way, and we refer to
them as ‘familial relative risks’.
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Abstract
A recent analysis by the Collaborative Group on Hormonal Factors in Breast Cancer has provided the
most precise quantification to date of the familial risks of breast cancer. The familial relative risks are
shown to decrease from more than fivefold in women younger than age 40 years with a first-degree
relative aged younger than 40 years at diagnosis, to 1.4-fold in women older than 60 years with a
relative diagnosed over age 60 years. These risks increase progressively with the number of affected
relatives. The risks associated with an affected mother and an affected sister are similar, and the
relative (but not absolute) risks are similar in subgroups defined by other established breast cancer risk
factors. These results provide a useful basis for counselling of women with a family history of breast
cancer, and they have implications for the genetic basis of the disease.
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As anticipated, the familial relative risk of breast cancer
declines progressively as both the age at diagnosis of the
case and the age at diagnosis of the relative increases.
The estimated relative risk is thus 5.7-fold when both the
case and the relative are younger than age 40 years, but is
only 1.4-fold when both are aged older than 60 years. (An
anomalous observation here is that the relative risks
decline more clearly with age of the case than with age of
the relative; for cases older than age 60 years, there was
no apparent trend in risk by age of relative. This anomaly
might be explicable by inaccuracies in the reporting of a
relative’s age at diagnosis.)
This pattern of risk was essentially the same whether the
affected relative was a mother or a sister. For women aged
younger than 50 years, the risk ratio associated with having
a relative diagnosed younger than age 50 years was 2.41
(95% confidence interval, 1.86–3.12) for an affected
mother and was 3.18 (95% confidence interval,
2.15–4.72) for having an affected sister. For women aged
older than 50 years, the risk ratio associated with having a
relative diagnosed older than 50 years was 1.60 (95%
confidence interval, 1.38–1.84) for an affected mother and
was 1.44 (95% confidence interval, 1.19–1.73) for an
affected sister.
The second observation was that the risk increased pro-
gressively with numbers of affected relatives. The risk
ratios were 1.80 with one affected relative, 2.93 with two
affected relatives and 3.90 (albeit with wide confidence
limits) with three or more affected relatives.
Third, the investigators performed detailed analyses to
examine the effects of other known breast cancer risk
factors in women with and without a family history, and
conversely the effect of family history in women in cate-
gories defined by other risk factors. They found that the
relative risks associated with other risk factors were
essentially identical in women with and without a family
history. In women with a family history, risk thus reduced
with increasing parity, with earlier age at first child, and
with earlier age at menopause to a similar relative extent
(but, therefore, a larger absolute extent) as in women
without a family history. There was no significant evidence
of an association of oral contraceptives or hormone
replacement therapy in women with a family history, but
the confidence limits for these comparisons were
extremely wide and the results were consistent with
effects similar to the small increased risks seen in the
general population.
Finally, the investigators examined the effect of tumour
spread on familial risk, but found that the familial risks
were essentially the same whether or not the tumour was
localised to the breast at diagnosis.
Limitations of the results
An obvious concern in any studies of familial risk is the
accuracy of reporting of cancer diagnoses in relatives.
Other studies have indicated that breast cancer is fairly
accurately reported, certainly in comparison with other
cancer types (for example, [2]), but there is some inaccu-
racy, and hence potentially some bias in favour of report-
ing of cancers by cases. However, the investigators found
the familial risks from the cohort studies alone (which are
not susceptible to this bias) to be very similar.
The main application of these results will be to genetic
counselling and identification of high-risk women for
screening and intervention studies. There are clearly some
important limitations in this respect. Most obviously, the
overview did not include data on genotypes at known sus-
ceptibility genes (data that would rarely be available in
such studies), so these risk estimates would not apply in
families where, for example, BRCA1 or BRCA2 mutation
testing had taken place. At least for the present, however,
genetic testing is mostly restricted to women with a strong
family history (e.g. three or more affected relatives) so
these empirical estimates will still be of value to the large
majority of women.
A more subtle problem is that no data on ages of unaf-
fected female relatives were included. Clearly, in practice,
the number and ages of unaffected female relatives do
affect risk (although to a lesser extent than affected rela-
tives do). Also, the overview had insufficient data to evalu-
ate risks according to whether a daughter was affected,
and no data at all on second-degree or more distant rela-
tives (generally poorly recorded in case–control studies
[2]). The latter two issues might be answered more reliably
through cohort studies of families, such as those based on
the Swedish Population Family Register [3].
The overview did not consider risks according to cancers
other than breast cancer in relatives. Other studies,
however, have indicated that, with exception of a well
established but modest risk of ovarian cancer (probably
explicable in terms of the association of both cancers with
BRCA1/2 mutations) and an association with childhood
sarcoma (perhaps entirely due to TP53 mutations), there
is little or no excess risk of breast cancer associated with
a family history of other cancers [4].
Implications of the results for breast cancer
genetics
Although the aim of the overview was to present empirical
risk estimates, these estimates do raise some interesting
issues with regard to the genetics of breast cancer. Two
studies have estimated that mutations in the BRCA1 and
BRCA2 genes only account for approximately 15% of the
excess familial risk of the disease [5,6], while the contribu-
tion of the other known breast cancer susceptibility genes181
(TP53, PTEN, CHK2 and ATM) is even smaller [7]. The
contribution of known genes is higher than this in certain
populations where specific BRCA1 or BRCA2 mutations
have become common as a result of founder effects. These
populations include Iceland, Ashkenazi Jewish populations
and parts of Poland. In most Western populations,
however, the observed familial risks are largely the result
either of other genes or of nongenetic familial risk factors.
While the possibility of the latter cannot be definitively
ruled out, results from twin studies suggest that the major-
ity of the familial risk is in fact genetic in origin [8,9]. (Since
adjustment for known reproductive and other breast cancer
risk factors had essentially no effect on the familial risks,
nongenetic contributors to the familial risk, if there are any,
must presumably be unrelated to the known risk factors.)
The absence of substantial difference in risk by type of
affected relative (i.e. affected mother versus affected sister)
suggests that the important genes are likely to act domi-
nantly or additively on risk, but not to act recessively (reces-
sive susceptibility genes give rise to higher risks in siblings
than in parents or offspring). Some studies using a family-
based cohort approach have found higher risks in siblings,
and these notably include studies of cases diagnosed at a
particularly young age [10,11]. These results do not neces-
sarily conflict with the overview, since the risk estimates
from the overview are imprecise at young ages. Conversely,
it may be that the higher risk to siblings in the cohort studies
is due at least in part to cohort effects on background inci-
dence rates, and to the artefactually low rate of breast
cancer in mothers who are, by definition, parous.
The pattern of risk by the number of affected relatives is
also revealing. The fact that the risk increases progres-
sively with the number of affected relatives suggests the
effect of a fairly large number of genetic risk groups, con-
sistent with, for example, a polygenic model as proposed
by Antoniou et al. [12]. The trend in relative risk with age
suggests that (like BRCA1 and, to a lesser extent,
BRCA2) some or all of the susceptibility genes involved
are likely to confer a higher relative risk at young ages.
Finally, the similarity of the risk ratios for other risk factors
in women with and without a family history suggest that
these risk factors act to a similar extent in women at any
level of genetic susceptibility. Of course, one cannot nec-
essarily assume that this will hold for carriers of particular
susceptibility mutations. Studies of BRCA1 and BRCA2
mutation carriers have shown that early menopause does
have the expected protective effect in these groups [13],
but the effects of other risk factors such as parity have not
been definitively established [14,15].
What are the implications for genetic counselling?
Perhaps the most important is that the absolute risk of
breast cancer in women with just one affected relative is
relatively modest, even when the relative is diagnosed at a
young age (the authors estimate a cumulative risk of 16%
by age 80 years for women with a relative diagnosed
younger than age 40 years). The risks associated with
having larger numbers of affected relatives are more sub-
stantial, and referral to cancer genetics clinics should
reflect this. The results of the present study also imply that
the effects of reproductive and hormonal risk factors could
be usefully incorporated into genetic counselling. Since
the effects of family history and these other risk factors on
breast cancer risks appear to combine in roughly multi-
plicative fashion, the absolute effects of risk factors in indi-
viduals with a strong family history can be substantial.
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